News
HKUMed research provides first evidence from a Chinese population to support review of long-term blood-monitoring for local clozapine use

02 November 2026

An international research team led by the Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has completed a long-term population-based research study to improve care for people with treatment-resistant schizophrenia (TRS), the most severe form of this mental health condition. The findings reinforce the importance of timely access to clozapine and provide the first large-scale evidence from a Chinese population to support a review of Hong Kong’s long-term blood-monitoring requirements. Currently, they require mandatory monthly blood tests while taking clozapine according to the existing guideline, which can impose a substantial burden on patients, their families and clinical services. The study was published in The British Journal of Psychiatry [link to the publication].

Clozapine is the only antipsychotic approved by the U.S. Food and Drug Administration specifically for TRS. While highly effective, concerns about neutropenia, a reduction in infection-fighting white blood cells, necessitates regular blood testing. In this HKUMed-led study, researchers examined 20 years of Hong Kong health-record data between 2003 and 2019, with follow-up until 2023. It compared data from 4,868 people who started clozapine with that of 38,277 people receiving other second-generation antipsychotics. The study found that the risk of clozapine-associated neutropenia was highest during the first 18 weeks of treatment and progressively decreased over time. After approximately two years, the risk profile was comparable to those with non-clozapine second-generation antipsychotics. The incidence of serious neutropenia was also very similar between the two groups.

Local evidence highlights optimal monitoring frequency 
The findings support concentrated surveillance during early treatment: weekly neutrophil monitoring for the first 18 weeks, followed by monthly monitoring for up to two years. Thereafter, monitoring frequency could potentially align with that of non-clozapine second-generation antipsychotics. Any changes should be implemented only through a formal review of Hong Kong’s clinical guidance, in alignment with evolving international standards, individual clinical assessment and appropriate safeguards.

Professor Sherry Chan Kit-wa, Department of Psychiatry, School of Clinical Medicine, HKUMed, and corresponding author of the study, said, ‘For people with TRS, clozapine can be life-changing, but the burden of monthly blood tests while taking the medication can discourage some patients from starting or continuing treatment. Our findings provide an evidence base for a careful, clinically-led review of how long-term monitoring can be made safer, more proportionate and less burdensome.’

The study also found that risk patterns varied by age and sex, suggesting that a personalised monitoring approach may be more appropriate than a one-size-fits-all model. The researchers stressed that patients should always consult their healthcare providers before making any changes to their medication or blood-testing schedules.

A sustained research programme on patient-centred outcomes
This monitoring study builds on two large-scale Hong Kong studies as part of the same research programme. In an 18-year population-based study of 9,456 people with schizophrenia, researchers found that continuous clozapine use was associated with a lower risk of suicide mortality and all-cause mortality than continuous treatment with other antipsychotics even after accounting for the use of additional antipsychotic medications. The findings were published in The British Journal of Psychiatry [link to the publication]. 

In a separate 20-year self-controlled study published in Biological Psychiatry [link to the publication], researchers examined 4,794 people who began clozapine treatment. The study found that periods of clozapine use were associated with substantially lower psychiatric-hospitalisation risk than periods of treatment with other antipsychotics. The risk of psychiatric-hospitalisation was 79% lower during the first clozapine treatment period and 73% lower during subsequent clozapine treatment periods. By comparing medication periods for the same individual, the study reduced the influence of inter-patient variability on the results.

Professor Chan said, ‘Taken together, these studies provide a more complete picture of both the benefits and risks of clozapine treatment. While careful monitoring remains important, the evidence suggests that clozapine can offer substantial benefits for people with TRS. We hope these findings will help reduce avoidable barriers to treatment, support informed decision-making between patients and healthcare professionals, and ultimately improve the quality of care for patients.’

The researchers emphasised that these observational studies demonstrate associations rather than definitely establishing that clozapine directly caused the observed outcomes. Nevertheless, the large territory-wide datasets, long follow-up periods and complementary study designs provide important real-world evidence for patients and clinicians in Hong Kong.

About the research team
The research is led by Professor Sherry Chan Kit-wa of the Department of Psychiatry, School of Clinical Medicine, HKUMed. The first author is Dr Zhou Huiquan, Post-doctoral Fellow from the same department. The team comprises HKUMed researchers and collaborators from Hong Kong public psychiatric services and international academic institutions. 

Acknowledgements
The mortality and hospitalisation studies were supported by the General Research Fund of the University Grants Committee, Government of the Hong Kong Special Administrative Region of the People’s Republic of China (HKSAR). The neutropenia study was supported by the Health and Medical Research Fund of the Health Bureau, the Government of the HKSAR. 

 

Media enquiries

Please contact LKS Faculty of Medicine of The University of Hong Kong by email (medmedia@hku.hk).

Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use.
The researchers hope the findings will help reduce avoidable treatment barriers, support informed decision-making, and improve patient care.